Dactolisib (BEZ235)

For research use only. Not for use in humans.

目录号：S1009 别名： NVP-BEZ235 中文名称：达克利司

CAS No. 915019-65-7

Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。在 3T3^TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Dactolisib可诱导自噬并抑制HIV-1的复制。Phase 2。

规格

价格

库存

购买数量

50mg	RMB 895.88	现货
200mg	RMB 2530.71	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dactolisib (BEZ235)发表文献416篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Sci Rep, 2022, 12(1):241

PubMed: 34997132 ( click the link to review the publication )

Curr Res Pharmacol Drug Discov, 2022, 3:100076

PubMed: 35005610 ( click the link to review the publication )

Nat Commun, 2021, 12(1):7268

PubMed: 34907175 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-21-1943

PubMed: 34921019 ( click the link to review the publication )

EMBO Mol Med, 2021, e14511

PubMed: 34779136 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 35(1):108940

PubMed: 33784499 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5736

PubMed: 34086347 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2139

PubMed: 33946744 ( click the link to review the publication )

Cancers (Basel), 2021, 13(11)2778

PubMed: 34204960 ( click the link to review the publication )

Cell Death Dis, 2021, 12(8):713

PubMed: 34272360 ( click the link to review the publication )
Cell Chem Biol, 2021, S2451-9456(21)00254-3

PubMed: 34111400 ( click the link to review the publication )

Clin Sci (Lond), 2021, CS20210571

PubMed: 34282832 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:621906

PubMed: 34124031 ( click the link to review the publication )

Oncogenesis, 2021, 10(1):8

PubMed: 33431808 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(20)11260

PubMed: 34681918 ( click the link to review the publication )

Int J Nanomedicine, 2021, 16:2173-2186

PubMed: 33758505 ( click the link to review the publication )

Sci Rep, 2021, 11(1):23302

PubMed: 34857796 ( click the link to review the publication )

Sci Rep, 2021, 11(1):10461

PubMed: 34002003 ( click the link to review the publication )

J Biol Chem, 2021, S0021-9258(21)00805-X

PubMed: 34303705 ( click the link to review the publication )

Int J Oncol, 2021, 10.3892/ijo.2021.5167

PubMed: 33491755 ( click the link to review the publication )

Neuroscience, 2021, S0306-4522(21)00070-1

PubMed: 33577953 ( click the link to review the publication )

SLAS Technol, 2021, 24726303211008858

PubMed: 33880947 ( click the link to review the publication )

J Burn Care Res, 2021, irz170

PubMed: 34213565 ( click the link to review the publication )

Biol Pharm Bull, 2021, 10.1248/bpb.b21-00531

PubMed: 34602526 ( click the link to review the publication )

Viruses, 2021, 13(6)1062

PubMed: 34205098 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Mol Cell, 2020, 80(6):1104-1122.e9

PubMed: 33259812 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Cell Rep, 2020, 32(12):108171

PubMed: 32966799 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )
Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E3058

PubMed: 33092134 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3689

PubMed: 33316942 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

J Mol Cell Biol, 2020, 12(8):644-653

PubMed: 31065693 ( click the link to review the publication )

Bioinformatics, 2020, btaa858

PubMed: 33067636 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-1017

PubMed: 32847978 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12888

PubMed: 33338300 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9240

PubMed: 33287446 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.3432

PubMed: 32976685 ( click the link to review the publication )
G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

Oncol Lett, 2020, 20(6):326

PubMed: 33123242 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )

Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1900-1918

PubMed: 32642299 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Can J Physiol Pharmacol, 2020, 10.1139/cjpp-2020-0280

PubMed: 32893666 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29926

PubMed: 32654229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):524

PubMed: 32963283 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

Elife, 2020, 9:e53367

PubMed: 32513387 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-4245

PubMed: 32605911 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):223-235

PubMed: 31776938 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11487

PubMed: 32661241 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )
Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Cell Death Differ, 2019, 26(3):548-564

PubMed: 30050055 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )
Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2019, 316(1):H61-H69

PubMed: 30359076 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Am J Transl Res, 2019, 11(10):6534-6543

PubMed: 31737204 ( click the link to review the publication )

Am J Transl Res, 2019, 11(12):7255-7271

PubMed: 31934276 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Oncol Rep, 2019, 10.3892/or.2019.7265

PubMed: 31524277 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

PLoS One, 2019, 14(5):e0216603

PubMed: 31100067 ( click the link to review the publication )

Reprod Sci, 2019, 1933719119828067

PubMed: 30791863 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Exp Ther Med, 2019, 18(3):2278-2284

PubMed: 31410178 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )
Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

ACS Pharmacol Transl Sci, 2019,

PubMed: 32259061 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2018,

PubMed: 30224486 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Virulence, 2018, 9(1):83-98

PubMed: 28475412 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )
Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )
Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10483-10496

PubMed: 29535821 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Sci Signal, 2017, 10(507)eaam7550

PubMed: 29184034 ( click the link to review the publication )

J Med Chem, 2017,

PubMed: 28471660 ( click the link to review the publication )

Cancers (Basel), 2017, 9(9)E125

PubMed: 28926938 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):102-115

PubMed: 27980105 ( click the link to review the publication )

Mol Oncol, 2017, 11(9):1130-1142

PubMed: 28544747 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )
J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10612

PubMed: 28878291 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12406

PubMed: 28963527 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Cell Cycle, 2017, 16(21):2146-2155

PubMed: 28910567 ( click the link to review the publication )

Oncotarget, 2017, 8(50):88043-88058

PubMed: 29152140 ( click the link to review the publication )

Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )
Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7265-7275

PubMed: 27980219 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

Oncogene, 2016, 35(38):5010-20

PubMed: 26973247 ( click the link to review the publication )

Cancer Lett, 2016, 374(2):250-60

PubMed: 26921131 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Biol Chem, 2016, 397(7):671-8

PubMed: 26910743 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )
Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65627-65642

PubMed: 27582537 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(34):54883-54896

PubMed: 27448972 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19214-27

PubMed: 27036037 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )
EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1593

PubMed: 25590803 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

Cancer Sci, 2015,

PubMed: 25483727 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

BMC Cancer, 2015,

PubMed: 26205886 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26270481 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Sci Signal, 2014, 7(349):ra102

PubMed: 25351247 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )
Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12862-76

PubMed: 25404640 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e827

PubMed: 24091670 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )
Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

J Biol Chem, 2013, 288(41):29821-35

PubMed: 23963458 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012,

PubMed: 22989520 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )
Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

靶点

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	点击更多
4 nM	5 nM	6 nM	7 nM	21 nM	点击更多

体外研究

BEZ235显著降低mTOR活化的激酶p70S6K的磷酸化水平。BEZ235导致S235/S236P-RPS6水平减少，IC50为6.5 nM。BEZ235抗mTOR的活性使用生化mTOR K-LISA试验测定，IC50为20.7 nM。BEZ235对其β旁系同源物的活性稍弱，IC50为75 nM。在人肿瘤细胞中，PI3K/Akt/mTOR通路经常被组成性活化。BEZ235阻断PI3K和mTOR激酶活性，通过结合于这些酶的ATP结合槽发挥作用。用逐渐增加浓度BEZ235处理PTEN-null细胞系PC3M和U87MG时，导致细胞增殖剂量依赖性减少，平均GI50为10-12 nM。^[1] BEZ235是一种mTORC1/2催化抑制剂。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MorxRY51cW2rY4LvZolidCCDc4PhfS=>		M3y5VFE5KGh?	NFrnOZNFVVOR	MmDxRY51cXS{eYDhco9{d22jbDDhZ5Rqfmm2eTD3bZRpKEWFNUCgc4YhOC5yMEK1JO69VQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUm0Okc,OjR6MEW5OFY9N2F-
MCF7	NHnafVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFX1dnAxNjBzLUGwNEDPxE1?	NFrUUYo1QCCq	MU\EUXNQ	NVm2dFRyUUN3ME2wMlc{KM7:TR?=	NE[0RZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3NVkxPCd-MkO4O\|E6ODR:L3G+
HCT116	M3jmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDIbHNVOC5yMT2xNFAh\|ryP	NFeydZA1QCCq	MVrEUXNQ	MV\JR\|UxRTFwMU[g{txO	NFHzW4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3NVkxPCd-MkO4O\|E6ODR:L3G+
U87MG	NYjSTII5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfGXo8xNjBzLUGwNEDPxE1?	NIqxTHU1QCCq	MofoSG1UVw>?	NECzNpNKSzVyPUGuN\|Ih\|ryP	Mn\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{G5NFQoRjJ\|OEexPVA1RC:jPh?=
HBC4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHld2RVOC5yMT2xNFAh\|ryP	NWLrTHBZPDhiaB?=		MXLMc4chT0l3ME2tPE43OSCP	MoHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
BSY1	NWm0dolvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfOTFZSOC5yMT2xNFAh\|ryP	NXrV[ncxPDhiaB?=		NFnTW4RNd2diR1m1NF0uQC52ODDN	NX;JTG5KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HBC5	NVPKfFN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXywMlAyNTFyMDFOwG0>	M4DTN\|Q5KGh?		MXXMc4chT0l3ME2tO{45PyCP	NIL2SFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
MCF7	MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXle4YxNjBzLUGwNEDPxE1?	NX[zTmNzPDhiaB?=		NXHTcVc6VG:pIFfJOVA:NThwMU[gUS=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MDA-MB-231	NEfzVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3HU415OC5yMT2xNFAh\|ryP	Mlr0OFghcA>?		M3zjUmxw\yCJSUWwQU05NjB7IF2=	MkPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
U251	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmO1NE4xOS1zMECg{txO	Mn\JOFghcA>?		NGWx[YJNd2diR1m1NF0uPy54NjDN	M4DDeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
SF268	NEDJ[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWL2UHlmOC5yMT2xNFAh\|ryP	M{HuWVQ5KGh?		NUj5d2E4VG:pIFfJOVA:NTdwOUKgUS=>	M{HQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
SF295	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDSfHdkOC5yMT2xNFAh\|ryP	NHPRV3E1QCCq		M4DMUmxw\yCJSUWwQU05NjNzIF2=	MmjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SF539	M4LEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV:ye29POC5yMT2xNFAh\|ryP	NV[1[Y5sPDhiaB?=		NGXhSmdNd2diR1m1NF0uQC53OTDN	NUXTUohoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
SNB75	Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoWyNE4xOS1zMECg{txO	M3zKOFQ5KGh?		NYDrU5RbVG:pIFfJOVA:NThwNUigUS=>	M1rPTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
SNB78	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXewMlAyNTFyMDFOwG0>	NIfldIo1QCCq		NGH4cZlNd2diR1m1NF0uQC54NTDN	M4OzPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HCC2998	M1j4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorRNE4xOS1zMECg{txO	MV60PEBp		NEnaToxNd2diR1m1NF0uQC5yNTDN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
KM12	NGjTc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1OxOFAvODFvMUCwJO69VQ>?	NV3HU\|BkPDhiaB?=		M3rlN2xw\yCJSUWwQU04NjV2IF2=	M1jZR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
HT-29	NXPYPVZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHWU3JUOC5yMT2xNFAh\|ryP	MVq0PEBp		MnyyUI9oKEeLNUC9MVcvPzViTR?=	NVL1XW5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
HCT15	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLRNE4xOS1zMECg{txO	NHu5eGU1QCCq		NIfi[XZNd2diR1m1NF0uQC5yMzDN	NHixSlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
HCT116	MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSwMlAyNTFyMDFOwG0>	MVW0PEBp		MXLMc4chT0l3ME2tO{43OSCP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
NCI-H23	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7UNE4xOS1zMECg{txO	MmHUOFghcA>?		NWKye5RQVG:pIFfJOVA:NTdwNkSgUS=>	NEHhdo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H226	NIfRUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTkW2twOC5yMT2xNFAh\|ryP	MWS0PEBp		NHT5dpdNd2diR1m1NF0uQC52NDDN	NVvoSHc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
NCI-H522	NF3YZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPONE4xOS1zMECg{txO	MWe0PEBp		MWrMc4chT0l3ME2tPE41PSCP	NH\TbVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOzOlI1Pid-MkKzN\|YzPDZ:L3G+
NCI-H438	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;GRnExNjBzLUGwNEDPxE1?	NUX3cpY6PDhiaB?=		M{i0Umxw\yCJSUWwQU05NjFzIF2=	NYrvRXFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
A549	NUjUS4ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[wMlAyNTFyMDFOwG0>	NHG0SIQ1QCCq		M{\ZNGxw\yCJSUWwQU05NjB5IF2=	Mmf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
DMS273	NWLxXGJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvCNE4xOS1zMECg{txO	MYG0PEBp		NEjFZ2hNd2diR1m1NF0uPy56MDDN	M2TzWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
DMS114	NEHkW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDRellqOC5yMT2xNFAh\|ryP	MWK0PEBp		M4C0Umxw\yCJSUWwQU05NjN7IF2=	NWHjNoU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
LOXIMVI	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3q2XlAvODFvMUCwJO69VQ>?	NGHLd2k1QCCq		NFfPe5RNd2diR1m1NF0uQC54NjDN	M3fCSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
OVCAR3	M1;3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXrSlcxNjBzLUGwNEDPxE1?	MU[0PEBp		NXT3XlMzVG:pIFfJOVA:NThwMUegUS=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
OVCAR4	NFzSToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3hXogxNjBzLUGwNEDPxE1?	MVW0PEBp		MVPMc4chT0l3ME2tPE42QCCP	MkDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
OVCAR5	NEjQcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTwOWcxNjBzLUGwNEDPxE1?	NWXKXld[PDhiaB?=		M3zmR2xw\yCJSUWwQU04NjV5IF2=	NYjDdmdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
OVCAR8	NHW4fXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjPXVMxNjBzLUGwNEDPxE1?	NFXpcm01QCCq		MofQUI9oKEeLNUC9MVcvQDRiTR?=	MkjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
SKOV3	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXTVGQxNjBzLUGwNEDPxE1?	NV3kRXpMPDhiaB?=		MVXMc4chT0l3ME2tPE41OSCP	M1PUNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
RXF631L	NYW3U29QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLZNE4xOS1zMECg{txO	MnXKOFghcA>?		NXnLVoFlVG:pIFfJOVA:NThwMkGgUS=>	NUf6VpY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
ACHN	M{PZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPJOmZmOC5yMT2xNFAh\|ryP	MYm0PEBp		NXvzTWdnVG:pIFfJOVA:NTdwOUWgUS=>	MojsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
St-4	MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjwNVkxNjBzLUGwNEDPxE1?	NYDLUpRjPDhiaB?=		MkT0UI9oKEeLNUC9MVcvPDdiTR?=	NUXrXpk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN1	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvnNE4xOS1zMECg{txO	Mm[4OFghcA>?		MmHsUI9oKEeLNUC9MVgvPDFiTR?=	M1jmZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O2NlQ3Lz5{MkOzOlI1PjxxYU6=
MKN7	NU\XW3ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LNeFAvODFvMUCwJO69VQ>?	MmDqOFghcA>?		Ml\IUI9oKEeLNUC9MVcvPjhiTR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
MKN28	NUHuN\|FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\mNE4xOS1zMECg{txO	MUC0PEBp		MmrOUI9oKEeLNUC9MVcvODdiTR?=	Mmr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{[yOFYoRjJ{M{O2NlQ3RC:jPh?=
MKN45	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Ht[FAvODFvMUCwJO69VQ>?	NVfhdVg3PDhiaB?=		M1\lZWxw\yCJSUWwQU05NjN2IF2=	NY\OUYFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
MKN74	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDUNE4xOS1zMECg{txO	M2LWN\|Q5KGh?		NHntOXNNd2diR1m1NF0uPy52MjDN	NV6yOplHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|YzPDZpPkKyN\|M3OjR4PD;hQi=>
DU145	NVqwVIdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7jNE4xOS1zMECg{txO	NHLhNVE1QCCq		NX\5VmlUVG:pIFfJOVA:NThwMU[gUS=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
PC3	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWiwMlAyNTFyMDFOwG0>	NVjwWXY4PDhiaB?=		M2C5S2xw\yCJSUWwQU05NjZ4IF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|NkK0Okc,OjJ\|M{[yOFY9N2F-
Trypanosoma brucei brucei	MY\GeY5kfGmxbjDBd5NigQ>?	M3jHelIxOCCwTR?=	NHjmeoIyOiCq	MoDOSG1UVw>?	Ml7kSIVkemWjc3WgbY4heGixc4Doc5Rq\HmuIHnuc5NqfG:uIIDoc5NxcGG2ZTDs[ZZmdA>?	NYnUO5lKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFU6PDZpPkK0PFA2QTR4PD;hQi=>
Trypanosoma brucei brucei	NH;iWGpHfW6ldHnvckBCe3OjeR?=		MXWxPEBp	MmrxSG1UVw>?	M3GyNGlvcGmkaYTpc44hd2ZicnXj[ZB1d3JvbXXkbYF1\WRiZX7kc4N6fG:\|aYOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5idILhcpNn\XK{aX6geZB1[Wun	NFz1Zo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEiwOVk1Pid-MkS4NFU6PDZ:L3G+
Trypanosoma brucei brucei	NXW2W2RGTnWwY4Tpc44hSXO\|YYm=	MVKyNFAhdk1?	Mn7ZNVIhcA>?	NI\6cIlFVVOR	NHXBO5FG\m[nY4Sgc44he3CqaX7nc416dGWrbjDs[ZZmdA>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhyNUm0Okc,OjR6MEW5OFY9N2F-
Trypanosoma brucei brucei	NF;tXHFHfW6ldHnvckBCe3OjeR?=	MYOyNFAhdk1?	MXixNkBp	MU\EUXNQ	MWXF[oZm[3Rib36gdIhwe3CqYYTp[Jlt[2ixbHnu[UBt\X[nbB?=	M1XOe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC1PVQ3Lz5{NEiwOVk1PjxxYU6=
UM-UC-3	M3jMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVyyO5lJUUN3ME2zNVUheE1?	Mln3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SBC-1	MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7VTWM2OD15NEKgdG0>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MKN1	MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXFSoZKSzVyPUKuPEBvVQ>?	NYTMXIZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H720	NWP6dnRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jrS2lEPTB;Mz61O{BvVQ>?	NV\BOoUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BFTC-909	M{jt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTFb2ZKSzVyPUOuO\|Ehdk1?	NHm0fFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BPH-1	M4nJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnkRXdKUUN3ME20Mlc3KG6P	Ml\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
PC-3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTVwMEmgcm0>	NVntVY5JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
AN3-CA	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\PbHk3UUN3ME21MlU3KG6P	NUHHfmFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HN	MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTVwOU[gcm0>	NXu2RZlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCC2218	M2LGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXMTWM2OD14Lk[xJI5O	M1\MPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KP-4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY[1TGIyUUN3ME23JI5O	M4LESlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LU-139	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnKOlBIUUN3ME23Mlc4KG6P	M2W4bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ETK-1	MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjP[GlKSzVyPUeuPFghdk1?	MlTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	NIXtU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPOR29KSzVyPUiuOFkhdk1?	NEnKWJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MHH-PREB-1	M3XjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTlwMUKgcm0>	NXnKeZlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DU-4475	NH;VcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzjSYs3UUN3ME25MlQ1KG6P	M4ixNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1666	MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jabGlEPTB;OT63NUBvVQ>?	M1rOW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CAMA-1	NFi5OnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPTTWM2OD17Lkigcm0>	NIr2[GI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TYK-nu	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTlwOUSgcm0>	MmDBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MFE-280	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTlwOUmgcm0>	M1jqOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A549	NGXYXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4GwcmlEPTB;MUCuNVQhdk1?	MnLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
769-P	NVjiW3J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIKyWnpKSzVyPUGwMlQ1KG6P	MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
L-363	NVvYXJJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvNOXBZUUN3ME2xNE43QSCwTR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ES8	M4HNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTFyLkmgcm0>	NHLHTIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
PA-1	MmfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHITWM2OD1zMT64NkBvVQ>?	NV3BUpdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Mewo	M1\URWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTFzLkm5JI5O	M1TTUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HSC-3	M4PnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYe5OopvUUN3ME2xNk4zOSCwTR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
H4	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\Xb2lEPTB;MUKuOlchdk1?	MmXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BB65-RCC	M{[5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTF{LkeyJI5O	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1793	NGHsN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXBSGxKSzVyPUGyMlgzKG6P	NF70Wnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KARPAS-45	M4HU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;rUGI5UUN3ME2xN{42OSCwTR?=	MlKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GCT	M4PFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTF\|Lk[4JI5O	M3jNc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EoL-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTF\|LkmzJI5O	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LB2241-RCC	NGL6cGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkGxTWM2OD1zND6wNUBvVQ>?	NFPs[XU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES5	NWrJcY9iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfJTWM2OD1zND63OEBvVQ>?	NUP4ZpRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LOXIMVI	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHHVYlKSzVyPUG0Mlk6KG6P	NG\YfWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COR-L105	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkL2TWM2OD1zNT6wOEBvVQ>?	NH:5[Hk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLo[VhKSzVyPUG1MlEhdk1?	NFf0Rmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CHL-1	M4XIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrhTWM2OD1zNT60OUBvVQ>?	MkXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
VMRC-RCZ	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfKOFM2UUN3ME2xOU43OyCwTR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HH	MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfoZ\|dKSzVyPUG1Mlchdk1?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NUGC-3	M1;uVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHKNZZKUUN3ME2xOk4{PCCwTR?=	MmTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EGI-1	Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWm0UGNpUUN3ME2xOk41OyCwTR?=	MmjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OS-RC-2	NIHCbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTF4LkS3JI5O	M4PnVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MOLT-16	NYPaXo9FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XobWlEPTB;MUeuNVUhdk1?	NVPyVnpJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H209	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3KzXmlEPTB;MUeuNlkhdk1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
697	NV[wWXRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrFW\|NKSzVyPUG3MlQ{KG6P	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
D-56MG	M{f0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLSTWM2OD1zNz62PUBvVQ>?	M4nJT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
VA-ES-BJ	M3mzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorKTWM2OD1zNz64N{BvVQ>?	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-16	Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfkTWM2OD1zOD6wOEBvVQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HGC-27	NFz0UW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWeweYhuUUN3ME2xPE4xPiCwTR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ES7	NUOxPYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTzTWM2OD1zOD6wPUBvVQ>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuH-7	NULaWoc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTF6LkSgcm0>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BCPAP	NGXRdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTF6Lk[1JI5O	Moe3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW1710	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYe0TJR[UUN3ME2xPE44OiCwTR?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
IST-MEL1	MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17CcGlEPTB;MUiuO\|chdk1?	MorlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SF295	NFL0T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\PeXVFUUN3ME2xPE46OyCwTR?=	M3;LOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RPMI-7951	M4jRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jXW2lEPTB;MUmuNlghdk1?	Ml;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SF126	NX7teJhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTF7LkSxJI5O	MnPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GAMG	NH\rW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF7LkS4JI5O	M2\QSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KNS-81-FD	NH3R[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTF7LkW0JI5O	NXvsU\|BbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RT-112	M{\pWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLu[Jd7UUN3ME2xPU43PiCwTR?=	NYDweIpZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DEL	M4mzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHXRZplUUN3ME2yNE41QSCwTR?=	MlXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CGTH-W-1	MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTJyLk[zJI5O	NVX6SlNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HOS	NUfnR\|lST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3qR2FzUUN3ME2yNU4xPiCwTR?=	MkjvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ES4	NGPJPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTJzLkC4JI5O	NWjlclZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
RXF393	Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\nbmlwUUN3ME2yNU41PSCwTR?=	NVvvU21DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H2030	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13R[WlEPTB;MkGuOVIhdk1?	NWjmXHBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
YH-13	NGq1WWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTJzLki4JI5O	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HT-1080	NYHZd2s4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjLd49KSzVyPUKxMlk{KG6P	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTJzLkm1JI5O	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
G-402	NF6ydJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojKTWM2OD1{Mj6xOkBvVQ>?	NH60[Jc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
786-0	M{TLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTJ{LkK5JI5O	M3rRXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
ME-180	NIHC[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTMTWM2OD1{Mj60N{BvVQ>?	NHn1[Hk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NB69	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTJ{LkWzJI5O	NIT3VnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
J-RT3-T3-5	MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ewfGlEPTB;MkKuPVYhdk1?	MknXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TGBC1TKB	M2G4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfKXVNKSzVyPUKzMlA2KG6P	NGXOeFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW780	MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrQTWM2OD1{Mz6xN{BvVQ>?	Ml2zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MG-63	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjoTWM2OD1{Mz60OUBvVQ>?	MorWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
BV-173	NGr2TIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnhWYtKSzVyPUKzMlg4KG6P	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CAL-51	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV36XlZMUUN3ME2yN{45QSCwTR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A375	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJ\|LkmzJI5O	M2GwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MEL-HO	NGP1elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTJ2LkC0JI5O	NYHSZ4NXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EFO-27	NUi4dGZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ2LkOzJI5O	NXPDb4w5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
Hs-578-T	NF\le2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEn6UVVKSzVyPUK0MlU5KG6P	Mke1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NBsusSR	NWXzc5Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2Hjb2lEPTB;MkSuOkBvVQ>?	NGDHc2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CTB-1	M2jZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvMTmFKSzVyPUK0MlY4KG6P	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
FTC-133	NXLyUVVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJ3LkGgcm0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MOLT-4	NFrUfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nFSGlEPTB;MkWuNVIhdk1?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HO-1-N-1	NETnc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3m3[2lEPTB;MkWuNVUhdk1?	NFXNZnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInKOlFKSzVyPUK1MlIzKG6P	MkKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
TI-73	MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnKTWM2OD1{NT6yPEBvVQ>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MPP-89	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknSTWM2OD1{NT6zNkBvVQ>?	NEe0NpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-150	M4DXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoD3TWM2OD1{NT64PUBvVQ>?	NXXzO3AyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LXF-289	NFHmOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPNcHp1UUN3ME2yOk4xPCCwTR?=	M{jTOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-LU-1	M3TqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jvWGlEPTB;Mk[uNVchdk1?	NGOyU\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HOP-92	MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzhTWM2OD1{Nj60PEBvVQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
HuO9	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPtTWM2OD1{Nj63OkBvVQ>?	Mm\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SW962	NET5OZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PmN2lEPTB;Mk[uO\|Yhdk1?	Ml;TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RS4-11	M4nuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn[0TWM2OD1{Nj65NUBvVQ>?	M1y5[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H292	MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIexdJZKSzVyPUK3JI5O	MnXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DB	NIeydYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTJ5LkO2JI5O	M3\sdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1088	Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTJ6LkK5JI5O	NGjRSJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A204	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LGZ2lEPTB;MkiuOFchdk1?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A3-KAW	NHPhN29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF30cHJKSzVyPUK4MlY1KG6P	NV:4Wm55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MV-4-11	NWjOWJBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJ6Lkegcm0>	NITQOWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
ES1	M1z0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTJ6Lki0JI5O	NUf0V25pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ONS-76	NHW5R5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXCOYkxUUN3ME2yPU4xPSCwTR?=	MmS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-263MG	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7YR5BKSzVyPUK5MlM2KG6P	NXfWXJhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
U-2-OS	NFvp[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoOzTWM2OD1{OT61JI5O	Ml71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
T98G	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHziZm1KSzVyPUK5Mlg5KG6P	MmrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
GI-ME-N	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTJ7LkmxJI5O	NYi4TFZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BHT-101	NVzCS5dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfadopKSzVyPUOwMlA2KG6P	NWn5T3BFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NOS-1	M3jMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVe0dFhbUUN3ME2zNE4yOiCwTR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
AsPC-1	NU\OdmRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nYfmlEPTB;M{CuNkBvVQ>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	NX7OZZRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjNOlJbUUN3ME2zNE43KG6P	M3HmeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
JVM-3	MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PIVWlEPTB;M{CuPFMhdk1?	MmDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KU-19-19	M{jGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mon5TWM2OD1\|MT6xN{BvVQ>?	NFfrOFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
OVCAR-8	NFfIU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfWVIZzUUN3ME2zNU4zPiCwTR?=	NIP1bnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BEN	M1rZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFG5OGRKSzVyPUOxMlY{KG6P	NUTXU\|MzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BE-13	NGfMOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTNzLkiyJI5O	NYXiSXlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EW-18	NYDPdWZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rNbmlEPTB;M{GuPFYhdk1?	NXzteoJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ECC10	MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTNzLkm1JI5O	MmC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CTV-1	NGHTVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVriSYdRUUN3ME2zNk45OiCwTR?=	NGPv[HY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
COLO-800	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfQT5lOUUN3ME2zNk46OiCwTR?=	Mn;sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A2058	NYP0U3F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIOycYVKSzVyPUOzMlI2KG6P	NIjwbZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
VM-CUB-1	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrvTY1KSzVyPUOzMlQ{KG6P	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
Ca9-22	MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NInMNldKSzVyPUOzMlU2KG6P	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COLO-684	NHjwPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{P0WmlEPTB;M{OuOVghdk1?	MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RPMI-8226	NHTiXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\Zd5lKSzVyPUOzMlgzKG6P	M1;OOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-NEP-1	M1vJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2D2WGlEPTB;M{SuNVUhdk1?	NHv2T2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
Becker	MmfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2WzWmlEPTB;M{SuNlEhdk1?	NUj1cZFGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H28	MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlW5TWM2OD1\|ND60OEBvVQ>?	NYfOUG1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAL-120	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rBdGlEPTB;M{SuO\|Ihdk1?	M{nMVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-157	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfqNIZKSzVyPUO1MlQyKG6P	MmLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
OVCAR-5	NGq1RpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXwVoVKSzVyPUO1MlQ4KG6P	NUT1cWNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LAMA-84	NHv4OVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\mOHpjUUN3ME2zOU45PyCwTR?=	MojoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAKI-1	NV7EcJVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTN4LkSzJI5O	Mn3EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Daoy	M2KyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HrTGlEPTB;M{[uO{BvVQ>?	Ml\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAL-62	M{P4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHETWM2OD1\|Nj64OkBvVQ>?	NE\Hd\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
8-MG-BA	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTN5LkK1JI5O	M2GwTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
8505C	M2T1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTN5LkWxJI5O	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LNCaP-Clone-FGC	NV\zdIhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoqxTWM2OD1\|Nz61PUBvVQ>?	NGHHfWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CAL-39	NHrYTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELRW2tKSzVyPUO3Mlkhdk1?	NHjKS\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MN-60	M2CzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDzTWM2OD1\|Nz65OkBvVQ>?	M1m5elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RKO	M3vsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXO1TXdUUUN3ME2zPE4{OyCwTR?=	NV;teFdwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
U251	MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DFdGlEPTB;M{iuOFMhdk1?	MoLsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SJSA-1	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHGwS4lKSzVyPUO4MlU1KG6P	MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAL-12T	M2LZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn;2TWM2OD1\|OD62JI5O	NGG5b5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC1419	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mme2TWM2OD1\|OD63NUBvVQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CO-314	Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfENoxKSzVyPUO4Mlc1KG6P	NWn0cFRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
LB1047-RCC	M1vqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTN6LkixJI5O	M2TJcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A101D	NVTBO5ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLhXIZbUUN3ME2zPE46PyCwTR?=	MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MDA-MB-175-VII	M{XCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoSzTWM2OD1\|OT61NUBvVQ>?	NFvsepc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MZ2-MEL	NWfDV2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPjTWM2OD1\|OT62OkBvVQ>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NB5	NXfQU4doT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTRyLk[0JI5O	NVr6fGlSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
G-401	NHTJXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzMfJpZUUN3ME20NE45OiCwTR?=	MmD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HT	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTRzLkCyJI5O	MoGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
8305C	MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjjTWM2OD12MT64O{BvVQ>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BHY	NGTxZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2e0NmlEPTB;NEKuO\|Ihdk1?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFK4VmNKSzVyPUSzJI5O	MlLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
T-24	NUe1VWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXB[4lpUUN3ME20N{45OyCwTR?=	M{nXOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EPLC-272H	M37EPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTR2LkO5JI5O	M4rzT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
PSN1	M4Wy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPIW3BKSzVyPUS0MlQhdk1?	MnznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2452	NID2U\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTR2LkW4JI5O	MmLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KS-1	NX\jbZVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTBTWM2OD12ND62OkBvVQ>?	NEPQdFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HD-MY-Z	NXraPXZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLkTWM2OD12ND65NkBvVQ>?	NXrSe24zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KNS-62	MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTR3LkO4JI5O	NVLxN4R4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NOMO-1	NF\zbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI[xWWtKSzVyPUS1Mlg4KG6P	NFnk[Ic9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-HEP-1	NH3aUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrqTWM2OD12Nj6wOEBvVQ>?	M4Gzd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
IGR-1	MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;1Xo9KSzVyPUS2MlE{KG6P	MmizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KYSE-180	M3u3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTR4LkG3JI5O	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EW-22	NIPYS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrlVpZKSzVyPUS2MlIhdk1?	M{TrflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1355	NFjLelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDPemZKSzVyPUS2MlM1KG6P	NE\CS4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
DOHH-2	NX3LN3M2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLNTWM2OD12Nj6zO{BvVQ>?	M4TlSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A4-Fuk	NGS3dW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NID6T\|VKSzVyPUS2MlUzKG6P	NYDRXY86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
PC-14	NWXm[ppLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TJdmlEPTB;NE[uOVchdk1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-5	MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2j4PWlEPTB;NE[uPFQhdk1?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LB996-RCC	M3vSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjGTWM2OD12Nz6xPUBvVQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1623	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHwb3FKSzVyPUS3Mlc3KG6P	MlXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1155	NFzuNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjtNlFKSzVyPUS4MlMzKG6P	MljSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LoVo	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvHTWM2OD12OD60JI5O	NHz2SnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MCF7	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13SWGlEPTB;NEiuOVghdk1?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
AGS	MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTR6Lke3JI5O	MkjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
PFSK-1	M1nSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HiZmlEPTB;NEmuNFYhdk1?	NH;LXGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
22RV1	NYnVe5JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYKzfGFjUUN3ME20PU4xQSCwTR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
COR-L23	NXL4fWpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHUTWM2OD12OT6xOkBvVQ>?	NGC5OGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
D-283MED	NXyxRZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljCTWM2OD12OT62NUBvVQ>?	NEX4VVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW982	NETuZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LsRmlEPTB;NEmuPVEhdk1?	NGDrOXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW620	MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmP5TWM2OD13MD6zOkBvVQ>?	NWTUZXJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KYSE-140	NETIUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTVyLkW1JI5O	M1joWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GCIY	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUm2dGNGUUN3ME21NE43PyCwTR?=	NF7ncmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MHH-ESS-1	MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLvTWM2OD13MT65OUBvVQ>?	Moj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-423MG	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIC3RW5KSzVyPUWyMlA5KG6P	NIG1TGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SF539	MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTwR3hKSzVyPUWyMlM2KG6P	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RPMI-2650	NUS4bFdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTV{Lk[5JI5O	M4fUcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
GR-ST	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHUTWM2OD13Mj64O{BvVQ>?	NGX0TZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
YKG-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TJR2lEPTB;NUOgcm0>	M{n4bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-MES-1	NISwWmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofKTWM2OD13Mz6yOkBvVQ>?	M1XMd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HLE	NGTsOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjhR2ZKSzVyPUWzMlQ4KG6P	NEjk[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RVH-421	M4LFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fMS2lEPTB;NUOuOlchdk1?	NU[1UGVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
C32	NGHhSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rDSGlEPTB;NUOuPFMhdk1?	NHnPSGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GB-1	M1LBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvNPFNzUUN3ME21OE4zKG6P	MoH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SNB75	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7pdoFsUUN3ME21OE4zPiCwTR?=	M{fvV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
EM-2	M4jLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlv1TWM2OD13ND60JI5O	MnHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
RH-1	NIW5SXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLjTWM2OD13ND63JI5O	Mo\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NKM-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTOTWM2OD13ND64NUBvVQ>?	MkOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2405	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPRTm1NUUN3ME21OE45QCCwTR?=	NF7vW4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-450	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTV3LkG2JI5O	M{HnWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
A704	M1ixRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fzTmlEPTB;NUWuOVkhdk1?	NF21bVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HAL-01	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlO4TWM2OD13NT64N{BvVQ>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
TE-11	M2nYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Dkc2lEPTB;NUWuPVkhdk1?	NUnMTYQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
DOK	NEDmeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTV4LkCyJI5O	M2XrWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KY821	M1z2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\yR5hqUUN3ME21Ok4zKG6P	NI\K[HY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KGN	NFrsT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHiSm0{UUN3ME21Ok4{OiCwTR?=	NGrF[I49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MC116	MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjadnEyUUN3ME21O{45KG6P	NWHxT5Y4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
PANC-08-13	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrUTINiUUN3ME21PE4xOSCwTR?=	Mor0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
KE-37	M{jzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTBWVlKSzVyPUW4Mlc4KG6P	NIDCZmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-410	NF[2SZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYWyRocxUUN3ME21PU41PyCwTR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RO82-W-1	NFj1ZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTV7Lkmgcm0>	MojlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
M14	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17tPGlEPTB;NkCuNFQhdk1?	NFzaNYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GI-1	NE\mb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTZyLkOgcm0>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
ML-2	NEPHVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\2e2lEPTB;NkCuOlIhdk1?	M4LuU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
BFTC-905	NFnSPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TKSmlEPTB;NkCuOlUhdk1?	Mn7TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
DMS-273	NX7BWZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYS1[mxuUUN3ME22NE45PyCwTR?=	M17RZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MDA-MB-361	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHQ[opNUUN3ME22NUBvVQ>?	M2rJZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MSTO-211H	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37HfWlEPTB;NkOuOVEhdk1?	NIq3enk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MEG-01	M{TlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\Fb5g{UUN3ME22N{42OiCwTR?=	NFfq[FI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
M059J	M1\VPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTZ\|LkW4JI5O	M1jtcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LN-405	MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWmwfZpFUUN3ME22N{45PSCwTR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1581	M1u0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\UZmJiUUN3ME22OE4xOyCwTR?=	M2PFW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TCCSUP	M1TTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnDTWM2OD14ND61N{BvVQ>?	M1XteVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW872	NIHtTnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfMZ4RnUUN3ME22OE42PyCwTR?=	NXnCc\|FzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KYSE-510	Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTZ3Lke1JI5O	M4DWWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H1792	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonGTWM2OD14Nj6xOUBvVQ>?	NU\Z[Y11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW13	Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTZ4LkWgcm0>	NEPJW4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
TE-8	NWHLZnppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M373OWlEPTB;Nk[uOVIhdk1?	M{fzN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SCH	NGHYPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPmNXJKSzVyPU[3MlEhdk1?	NVPNe5dkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NEC8	NFnVb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1T3XGlEPTB;NkeuNlQhdk1?	MmXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HuO-3N1	NHPHb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jBW2lEPTB;NkeuN\|Ehdk1?	NUDrN2R{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EFM-19	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnw[IxKSzVyPU[3MlUhdk1?	NH;MRm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HEC-1	M3LOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXL[lJKSzVyPU[3MlUzKG6P	NF\3R3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
T47D	NETQfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV34UnZpUUN3ME22O{45PyCwTR?=	NGn2TXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SNU-423	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTZ5Lkm4JI5O	NEXofpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
WM-115	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PaPWlEPTB;NkiuNVQhdk1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CaR-1	M3vFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUiwXGt[UUN3ME22PE4zPSCwTR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KU812	NWHyVGc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nyVGlEPTB;NkiuOlkhdk1?	M2DF[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
AM-38	NFvwSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfuenRKSzVyPU[5MlMyKG6P	NYTaZVU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KOSC-2	NYnHSW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjt[IxKSzVyPU[5Mlk4KG6P	NVjtOphiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
MC-IXC	NHvIUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETSdYRKSzVyPUewMlA5KG6P	MnvIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SCC-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXxTWM2OD15MT6zPEBvVQ>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
Calu-3	NFriNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX2TWM2OD15MT65PEBvVQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
RPMI-8866	NYPnPVA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jWemlEPTB;N{KuPFIhdk1?	NXzPXolwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OVCAR-4	NVXVfIJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjpWJBKSzVyPUezMlM3KG6P	NYT5Rph7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
OAW-42	NF7kcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWK1dpFrUUN3ME23N{4{QSCwTR?=	MnTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ATN-1	NInQTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fiZ2lEPTB;N{OuPFchdk1?	M2ey[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
CHP-212	NYT0bVhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlv3TWM2OD15ND65OUBvVQ>?	M2fXNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
C2BBe1	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTd3LkCzJI5O	NGLIb\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
A498	NHq0co5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HENmlEPTB;N{WuNVUhdk1?	NWTHZWVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SH-4	NYjwVnd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DtZ2lEPTB;N{WuNlEhdk1?	NF\RNmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SNU-449	NGXKeZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUG2Z5RuUUN3ME23OU44QSCwTR?=	M{HwSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
RD	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zNWmlEPTB;N{WuPFYhdk1?	NVHTfoNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
PANC-03-27	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ixZmlEPTB;N{[uNlUhdk1?	NUXW[G1rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
S-117	M3TEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPwU3JKSzVyPUe2MlI4KG6P	NH24fW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-MEL-2	NYTZdlBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DpdmlEPTB;N{[uO\|Uhdk1?	M3;1SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LK-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7MTWM2OD15Nz6wOUBvVQ>?	MkPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CP50-MEL-B	MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTd5LkSgcm0>	NH\QcVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
647-V	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoO3TWM2OD15OD6wO{BvVQ>?	M3HFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LU-134-A	NWLOcW1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7lTWM2OD15OT6wN{BvVQ>?	M1O0N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
5637	M{HnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1fXeGlEPTB;N{muNlMhdk1?	NHnBXXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1437	Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnYXpRKSzVyPUiwMlUhdk1?	MlixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H460	Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXRfHlKSzVyPUixMlI{KG6P	NVTScIh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BxPC-3	NXLVNotJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRThzLkS2JI5O	NV2yVnptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAN	MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorJTWM2OD16MT64OEBvVQ>?	M1n0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KINGS-1	NE\ESXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1i0PWlEPTB;OEKuN\|Ihdk1?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
OCUB-M	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTh{LkSxJI5O	NV\zR2hMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KALS-1	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXNNHNlUUN3ME24Nk42PCCwTR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
OCI-AML2	NG\QeXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPueIVKSzVyPUiyMlYyKG6P	MnLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
A253	M4T2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\mTlFKSzVyPUiyMlY2KG6P	M2XOTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
LCLC-97TM1	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjHW2plUUN3ME24Nk45PiCwTR?=	Mo\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H520	NHH0PHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTlTWM2OD16Mz6wOkBvVQ>?	NHPaNGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
P30-OHK	NUjqblhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjX[lJKSzVyPUizMlUhdk1?	NIS3WVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SBC-5	NX7UZlVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLqTWM2OD16Mz61NkBvVQ>?	NVXZXlJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HCE-T	NFzLfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmntTWM2OD16Mz63OEBvVQ>?	NX76dWhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
JEG-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\CS2lEPTB;OESuNUBvVQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
KG-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTh2LkK0JI5O	M4K2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
MIA-PaCa-2	Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXSfGZKSzVyPUi0MlU1KG6P	Mn\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
CAL-33	MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\PdGlEPTB;OEWuNFghdk1?	NGLyXJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
639-V	NVv3RnViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HIT2lEPTB;OEWuOFIhdk1?	NF:0UIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1048	NHzjZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTh4LkOxJI5O	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1573	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPxTWM2OD16Nz60PEBvVQ>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H2228	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3kVVd[UUN3ME24PE4zPiCwTR?=	NYT1ZpVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NB14	NYXkOW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEW0elJKSzVyPUi4MlMhdk1?	M{PTR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SCC-25	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITPU\|dKSzVyPUi5MlgzKG6P	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A431	NWDtdm4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTh7Lkm3JI5O	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
SN12C	M2L5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvQTWM2OD17MD62NkBvVQ>?	M3LIR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HuCCT1	NX3MVHZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3ZdJRKSzVyPUmwMlc3KG6P	MlTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LS-123	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITZXYtKSzVyPUmyMlE5KG6P	NXXCZ5pERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
CAL-85-1	NVPWXmExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTl{LkS4JI5O	NXrOR\|d5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
ES6	NVn3dYJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{Pp[mlEPTB;OUKuPFMhdk1?	NW\5SlhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NCI-H650	NGLWRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTiTWM2OD17ND6wPUBvVQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H446	M2WxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvkWYtQUUN3ME25OU4yOiCwTR?=	MnrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-13	MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfHW2JKSzVyPUm1Mlc2KG6P	NGjBc5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HSC-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfZZVJiUUN3ME25OU45QSCwTR?=	NVjOSXA1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
U031	NF\pXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTl4LkezJI5O	NXjJNGRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
EW-11	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTyNVU5UUN3ME25Ok45QCCwTR?=	NWTGfZA5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
GAK	M3PqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HGR2lEPTB;OUiuPVMhdk1?	MnTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SK-OV-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DVTmlEPTB;MUCwMlA4KG6P	M4TWO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
OMC-1	MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmT6TWM2OD1zMECuNVghdk1?	M1rUfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TK10	NF[2PYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r0fmlEPTB;MUCwMlIyKG6P	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
EKVX	M3\JNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXj0WlZ6UUN3ME2xNFAvPiCwTR?=	M3LielxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
Detroit562	NVXVboRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHSTWM2OD1zMEKuNVchdk1?	NFjwO\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SF268	M4nIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFyMj6zOEBvVQ>?	M2jmOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SNU-387	NH3QZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPzTWM2OD1zMESuNVchdk1?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MDA-MB-231	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Xmc2lEPTB;MUC1MlA3KG6P	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1563	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jSUmlEPTB;MUC1MlE5KG6P	MlL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
D-502MG	NUPuZmhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojITWM2OD1zMEWuO{BvVQ>?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
A2780	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFyNj60O{BvVQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
IA-LM	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlS1TWM2OD1zMEeuOVEhdk1?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
D-392MG	MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDuVWlKSzVyPUGwO{42PCCwTR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MS-1	NEXaWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfTflJKSzVyPUGwO{44OSCwTR?=	NXPJTHl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW1990	MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HkXGlEPTB;MUC4MlU1KG6P	M{LONlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HEL	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTFyOT6yPUBvVQ>?	NIq1TJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SW1573	M123dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXBRW9KSzVyPUGwPU4{OSCwTR?=	M{S2XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SW1783	NHTtfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnKTWM2OD1zMUCuNlIhdk1?	NVjtfYdQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-680N	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fJcWlEPTB;MUGwMlc3KG6P	NHe1dpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-N87	NE\vOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTFzMT6wOEBvVQ>?	M1KwSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-MEL-28	NUfKdI9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTFzMT61OUBvVQ>?	NHfrU3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
BT-20	NFzpXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTFzMj6wNUBvVQ>?	NHLxZm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1648	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\5PZRCUUN3ME2xNVMhdk1?	MkXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
no-11	NWGyeHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGr2WHpKSzVyPUGxN{4zQCCwTR?=	NGnEW5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
MOLT-13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn\OTWM2OD1zMUOuOFQhdk1?	M2PkT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
NCI-H2170	NH3mfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELFcFFKSzVyPUGxOE42OSCwTR?=	NWXLeZhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HTC-C3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;GOIxqUUN3ME2xNVYvQDVibl2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
LU-99A	NUjQb2NYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTFzNz6yNUBvVQ>?	M{jsVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HCC2998	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3:xfGlEPTB;MUG3MlkzKG6P	NIXGZXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NB13	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFzNz65PUBvVQ>?	NG\sW5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
GT3TKB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7kTJFKSzVyPUGxPE4xQCCwTR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
BT-549	MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDpemhFUUN3ME2xNVgvQTVibl2=	MkPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H747	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTFzOT6zOEBvVQ>?	Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
EW-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1H4NWlEPTB;MUKwMlIhdk1?	NGTVSYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
LB831-BLC	NH3SNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1T1XWlEPTB;MUKwMlY{KG6P	NVy3VVF4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
NMC-G1	NHL5RnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3RRWw2UUN3ME2xNlEvOTFibl2=	NUezWYwyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
COLO-679	M{fad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7NOJpKSzVyPUGyNk4yPSCwTR?=	M2i4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
HL-60	NInCSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGOyV3VKSzVyPUGyN{4yKG6P	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MKN7	MoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvRTWM2OD1zMkOuPFMhdk1?	NHPMbWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
RERF-LC-MS	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjWbHVVUUN3ME2xNlQvOzFibl2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
DMS-114	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHkfWhRUUN3ME2xNlUvODlibl2=	NUCwPXpwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
HuP-T4	NWjPVmNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzjXGFKSzVyPUGyOk46PyCwTR?=	NIPS[2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HCC2157	Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF{Nz61JI5O	MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
SKG-IIIa	NUPGeGRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYO2dWx6UUN3ME2xNlgvQCCwTR?=	MmXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
HCT-116	NFjZS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX:1U4tmUUN3ME2xN\|AvPjRibl2=	NYDDeIRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
BB30-HNC	M1P2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTF\|MD63PEBvVQ>?	M4rNflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
KYSE-270	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rGSWlEPTB;MUOwMlg5KG6P	MkP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
MFM-223	NWO5TYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjmbnBKSzVyPUGzNU42OSCwTR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NH-12	NFK2[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIH2THRKSzVyPUGzNk46QSCwTR?=	NW\x[ZJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
U-118-MG	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\XbG5KSzVyPUGzN{43OiCwTR?=	MkPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
ESS-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rmNmlEPTB;MUO1MlE5KG6P	M2HaXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
D-247MG	NEHvNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWe4Vms{UUN3ME2xN\|UvOjFibl2=	NIn0bVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
IGROV-1	NEXnVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TiTGlEPTB;MUO1Mlc3KG6P	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
C-33-A	M3n3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTF\|NT65O{BvVQ>?	MoTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1693	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnNeGNKSzVyPUGzOk4yOiCwTR?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
MLMA	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfQOFRKSzVyPUGzOk42QCCwTR?=	NETOWJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-N-AS	NHT1Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NET2RppKSzVyPUGzO{4yPyCwTR?=	MkHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H1755	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LhO2lEPTB;MUO4Mlg2KG6P	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
CHP-134	NYLnTmhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrCOpZLUUN3ME2xN\|kvPTVibl2=	MlPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LS-513	MoXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnv1TWM2OD1zNECuPVEheE1?	M3TIeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
TE-12	NGDrUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XqfWlEPTB;MUSwMlk{KG6P	NXH4cplHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
KNS-42	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XSSmlEPTB;MUS0MlMhdk1?	M4\5S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SJRH30	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjneWVKSzVyPUG0OE41PCCwTR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFc6PDZ\|Lze+V2FPT0WUPD;hQi=>
NCI-H1092	M1roeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEj5c3dKSzVyPUG0OE42OiCwTR?=	NXXyNYZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
H-EMC-SS	M33PUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LkR2lEPTB;MUS2MlgyKG6P	M4q3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5Pzl2NkOvK\|5USU6JRWK8M4E,
SK-MEL-3	NVHKcJFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTBTWM2OD1zNEeuOVUhdk1?	NH:1Tmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
SK-N-FI	NYH0ZlJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fPbWlEPTB;MUS3MlU6KG6P	MortQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
NCI-H2126	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjrS\|I2UUN3ME2xOFgvOTVibl2=	NFTVdVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H1299	M3\vSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLyTWM2OD1zNUCuNlIhdk1?	NFzkSFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
CFPAC-1	M3TuSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P6eGlEPTB;MUWwMlY3KG6P	NELIcFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
NCI-H661	NGHOSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTF3MT6yOkBvVQ>?	NFXEcGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
KYSE-70	NEG4OW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7HTWM2OD1zNUGuO\|khdk1?	NUDHempjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh5OUS2N{8oRlODTlfFVlww[T5?
SW900	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37LeGlEPTB;MUW0MlY2KG6P	MmPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
Ca-Ski	NHntNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13m[WlEPTB;MUW2MlM6KG6P	NFvrVmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?
HPAF-II	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTF3Nj60O{BvVQ>?	Ml:wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg4QTR4Mz:nQnNCVkeHUkyvZV4>
LB2518-MEL	MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1n6NWlEPTB;MUW3MlEhdk1?	NHjsSpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDd7NE[zM{c,W0GQR1XSQE9iRg>?

研究领域

产品类型